Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 3/20 | 0.40 |
| ▸ | METAP1 | P53582 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599048 | 1.00 | CYP2D6 (0.50) | CYP2D6DPP4ANPEPENPEPMETAP2 | |
| SCHEMBL27689737 | 1.00 | CYP2D6 (0.50) | CYP2D6DPP4ANPEPENPEPMETAP2 | |
| SCHEMBL3616232 | 0.83 | ANPEP (0.39) | CYP2D6DPP4ANPEPENPEP | |
| SCHEMBL3616228 | 0.83 | ANPEP (0.39) | CYP2D6DPP4ANPEPENPEP | |
| SCHEMBL4433202 | 0.81 | REN (0.50) | CYP2D6METAP2METAP1REN | |
| SCHEMBL4441935 | 0.81 | REN (0.50) | CYP2D6METAP2METAP1REN | |
| SCHEMBL4433209 | 0.81 | REN (0.50) | CYP2D6METAP2METAP1REN | |
| SCHEMBL3601886 | 0.79 | CYP2D6 (0.51) | CYP2D6METAP2METAP1EPHX1 | |
| SCHEMBL5511382 | 0.79 | DPP4 (0.47) | DPP4REN | |
| SCHEMBL8270363 | 0.77 | CTSK (0.52) | METAP2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | CYP2D6 1615/4885DPP4 14/4885ANPEP 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.